Health and economic impacts of Lassa vaccination campaigns in West Africa
Open Access
- 28 August 2024
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 30 (12) , 3568-3577
Abstract
Lassa fever is a zoonotic disease identified by the World Health Organization (WHO) as having pandemic potential. This study estimates the health-economic burden of Lassa fever throughout West Africa and projects impacts of a series of vaccination campaigns. We also model the emergence of ‘Lassa-X’—a hypothetical pandemic Lassa virus variant—and project impacts of achieving 100 Days Mission vaccination targets. Our model predicted 2.7 million (95% uncertainty interval: 2.1–3.4 million) Lassa virus infections annually, resulting over 10 years in 2.0 million (793,800–3.9 million) disability-adjusted life years (DALYs). The most effective vaccination strategy was a population-wide preventive campaign primarily targeting WHO-classified ‘endemic’ districts. Under conservative vaccine efficacy assumptions, this campaign averted $20.1 million ($8.2–$39.0 million) in lost DALY value and $128.2 million ($67.2–$231.9 million) in societal costs (2021 international dollars ($)). Reactive vaccination in response to local outbreaks averted just one-tenth the health-economic burden of preventive campaigns. In the event of Lassa-X emerging, spreading throughout West Africa and causing approximately 1.2 million DALYs within 2 years, 100 Days Mission vaccination averted 22% of DALYs given a vaccine 70% effective against disease and 74% of DALYs given a vaccine 70% effective against both infection and disease. These findings suggest how vaccination could alleviate Lassa fever’s burden and assist in pandemic preparedness.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- Lassa fever vaccine use cases and demand: Perspectives from select West African expertsVaccine, 2024
- The global burden of neglected zoonotic diseases: Current state of evidenceOne Health, 2023
- Epidemiological characteristics of Lassa fever cases in Liberia: a retrospective analysis of surveillance data, 2019–2020International Journal of Infectious Diseases, 2022
- Acute kidney injury and mortality in pediatric Lassa fever versus question of access to dialysisInternational Journal of Infectious Diseases, 2021
- Lassa Fever Induced Hearing Loss: The Neglected Disability of Hemorrhagic FeverInternational Journal of Infectious Diseases, 2020
- Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018PharmacoEconomics, 2020
- Clinical Sequencing Uncovers Origins and Evolution of Lassa VirusCell, 2015
- Costs of vaccine programs across 94 low- and middle-income countriesVaccine, 2015
- Valuing vaccines using value of statistical life measuresVaccine, 2014
- Strain-specific antibody response to Lassa virus in the local population of west AfricaJournal of Clinical Virology, 2008